Neuro-oncology: Novel molecular targets in treatment of glioblastoma

Nature Reviews Neurology

Volumn 9, Issue 11, 2013, Pages 612-613

  Sanson, Marc ^a   Idbaih, Ahmed ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; ISOCITRATE DEHYDROGENASE 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN MDM2; PROTEIN P53;

ARTICLE; CARCINOGENESIS; CTNND2 GENE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DNA METHYLATION; DRUG TARGETING; EGFR GENE; EGFR PDPH GENE; EGFR SEPT14 GENE; FGFR3 TACC1 GENE; FGFR3 TACC3 GENE; FUSION GENE; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GLIOBLASTOMA; HUMAN; IDH1 GENE; LZTR1 GENE; MDM2 GENE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; ONCOGENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PTEN GENE; SYNDROME DELINEATION; TUMOR SUPPRESSOR GENE;

BRAIN NEOPLASMS; GENOMICS; GLIOBLASTOMA; HUMANS;

EID: 84887258322     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2013.210     Document Type: Article

References (10)

1. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
2. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
3. Frattini, V. et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat. Genet. 45, 1141-1149 (2013).
4. Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010).
5. Carro, M. S. et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463, 318-325 (2010).
6. Singh, D. et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337, 1231-1235 (2012).
7. Idbaih, A., Ducray, F., Sierra Del Rio, M., Hoang-Xuan, K. & Delattre, J. Y. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors. Oncologist 13, 978-992 (2008).
8. Stommel, J. M. et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287-290 (2007).
9. Sottoriva, A. et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl Acad. Sci. USA 110, 4009-4014 (2013).
10. Burrell, R. A., McGranahan, N., Bartek, J. & Swanton, C. The caus es and consequences of genetic heterogeneity in cancer evolution. Nature 501, 338-345 (2013).